It has been shown recently that matrix metallopro teinases (MMPs) are elevated after cerebral ischemia, In the current study, we investigated the pathophysiologic role for Ec'3.4.24,35) in a mouse model of per manent focal cerebral ischemia, using a combination of genetic and pharmacologic approaches, Zymography and Western blot analysis demonstrated that MMP-9 protein levels were rapidly up-regulated in brain after ischemic onset. Reverse transcrip tion polymerase chain reaction showed increased transcription of MMP-9, There were no differences in systemic hemodynam ic parameters and gross cerebrovascular anatomy between wild type mice and mutant mice with a targeted knockout of the Matrix metalloproteinases (MMPs) form a family of at least 16 zinc-dependent endopeptidases that are collec tively able to degrade, or modify, or both, almost all proteinaceous components of the extracellular matrix (ECM) (Nagase and Woessner, 1999 
MMP-9 gene, After induction of focal ischemia, similar reduc tions in cerebral blood flow were obtained. In the MMP-9 knockout mice, ischemic lesion volumes were significantly re duced compared with wild type littermates in male and female mice, In normal wild type mice, the broad spectrum MMP inhibitor BB-94 (batimastat) also significantly reduced isch emic lesion size, However, BB-94 had no detectable protective effect when administered to MMP-9 knockout mice subjected to focal cerebral ischemia, These data demonstrate that MMP-9 plays a deleterious role in the development of brain injury after focal ischemia. Key Words: Stroke-Proteolysis-Extracellular matrix-Neuroprotection-Gene knockout-Mouse, et aI., 1995), transforming growth factor 1-13 (TGFI-B) (Yu and Stamenkovic, 2000) , and pro-fibroblast growth factor receptor 1 (Levi et aI., 1996) . Matrix metallopro teinases play important roles in many physiologic pro cesses, including embryologic remodeling, wound heal ing, angiogenesis, bone remodeling, ovulation, and im plantation (Nagase and Woessner, 1999) , Because MMPs can degrade many components of the ECM, enzyme activities are strictly regulated (Fini et aI., 1998) . Protein levels are regulated at the transcriptional level of expression, More importantly, however, pro enzyme activation and enzyme activities are tightly regu lated by tissue inhibitors of MMP (TIMP) and interac tions with surrounding ECM molecules. Uncontrolled expression of MMPs can result in tissue injury and in flammation, Recently, abnormal MMP activity has been implicated in cerebral ischemia, In mouse, rat, and ba boon models of cerebral ischemia, MMP-2 and MMP-9 expression were significantly increased after ischemic onset (Gasche et aI., 1999; Heo et aI., 1999; Mun-Bryce and Rosenberg, 1998; Rosenberg et aI., 1996) , Treatment with MMP inhibitors reduced the formation of vasogenic edema in a rat model of focal cerebral ischemia (Rosen berg et a!., 1998), and treatment with an MMP neutralizing antibody reduced infarct size (Romanic et aI., 1998) . Taken together, these studies suggest that the MMP family of proteinases participates in the patho physiology of cerebral ischemia. However, direct evi dence for the role of specific MMPs remains to be elucidated.
In the current study, we investigated the hypothesis that MMP-9 (gelatinase B, EC.3.4.24.35) may be a par ticipant in the pathophysiologic cascade of neuronal tis sue damage after focal cerebral ischemia. This hypoth esis was tested by performing experiments in a mouse model of middle cerebral artery occlusion. First, we documented through zymography, Western blots, and re verse transcription polymerase chain reaction (RT-peR) that MMP-9 was indeed up-regulated in ischemic brain. Next, we showed that ischemic lesion volumes were sig nificantly reduced in mutant mice with a targeted knock out of the MMP-9 gene. A complementary experiment showed that the broad spectrum MMP inhibitor B8-94 (batimastat) reduced ischemic lesion volumes in normal wild type mice. However, BB-94 had no significant ef fect when administered to MMP-9 knockout mice. These findings support a deleterious role for MMP-9 in the pathophysiology of brain damage after focal ischemia.
MATERIALS AND METHODS

Animal model
All experiments were performed according to an institution ally approved protocol in accordance with NIH Guide for the Care and Use of Laboratory Animals. Normal male CD-I mice were used in experiments that documented the ischemic up regulation of MMP-9 and experiments that tested the cerebro protective properties of the broad spectrum MMP inhibitor BB-94 (batimastat). For all other experiments, the MMP-9 knock out strain and their corresponding wild type littermates (male and female) were used. The MMP-9 knockout mice were bred from a CD-I background (Vu et aI., \998) . To inactivate the MMP-9 gene, part of exon 2 and all of intron 2 were replaced with a cassette containing the neomycin phosphotransferase cDNA driven by the phosphoglycerate kinase promoter. Ho mozygous null mice were viable and fertile. The major pheno typic alteration detected was a perturbed pattern of skeletal growth plate development during the first three weeks of life, which eventually remodeled, resulting in an axial skeleton of normal appearance (Vu et aI., 1998 ). In the current study, a macroscopic examination of the knockout mice showed that the major cerebral arteries including the circle of Willis appeared normal, compared with wild type littermates and normal CD-I mice.
The standard intraluminal middle cerebral artery occlusion method was used. Briefly, mice were anesthetized with I-O.S% halothane in 30% oxygen and 70% nitrous oxide using a face mask. The right femoral attery was cannulated to record blood pressure and obtain arterial blood samples. Core rectal tem-J Cere" Blood Flow Meta". Vol. 20, No. 12, 2000 perature was maintained at 37.SoC with a thermostat-controlled heating pad. Following a midline skin incision, the right exter nal carotid artery was exposed, and its branches were electro coagulated. A 7.0 nylon monofilament coated with silicon was introduced into the right internal carotid artery through the external carotid artery to occlude the origin of middle cerebral artery. Sham control animals were subjected to similar opera tions to expose the carotid arteries without middle cerebral artery occlusion. All animals were assessed with laser-Doppler flowmetry to confirm adequate induction of focal ischemia, and for purposes of comparison of regional cerebral blood flow deficits between experimental groups.
Treatment with matrix metalloproteinase inhibitor Oxford, England) was used as a broad spectrum MMP inhibitor in focal cerebral ischemia. ICSO values for enzyme inhibition of representative MMP are as follows: S nmollL for MMP-l, 4 nmollL for MMP-2, 20 nmollL for MMP-3, 6 nmollL for MMP-7, and 3 nmollL for MMP-9 (Batimastat technical information sheet; British Biotech). Separate experiments were performed to as sess the effects of BB-94 in normal CD-l mice and MMP-9 knockout mice. In all studies, BB-94 was administered intra peritoneally as a suspension of 3 mg/mL in phosphate-buffered saline (PBS; pH 7.2) containing 0.01% Tween-80. The intra peritoneal route has led effective delivery of inhibitor to brain (Paez Pereda et aI., 2000) . Mice were treated twice, 30 minutes before and 3 hours after the start of the focal ischemic insult (SO mg/kg per dose). The timing of the second dose was based on the estimated 3-hour plasma half-life of BB-94 in mice (Low et aI., 1996) ; similar doses have been shown to be effective in hibitors of MMP activity in mouse tumor models (Goss et aI., 1998) . Untreated controls received PBS containing 0.0 I % Tween-80.
Measurement of neurologic deficits
Mice were tested and scored for neurologic deficits as fol lows: () = no detectable neurologic deficit; I = failure to extend left forepaw fully; 2 = spontaneous turning to the left; 3 = spontaneous circling to left; 4 = inability to move or retain normal upright posture. Assessments were made at 2 and 24 hours after middle cerebral artery occlusion.
Measurement of infarct volume
Mice were killed 24 hours after ischemic onset. Eight coro nal sections per brain (I-mm-thick) were prepared and stained with 2.3.S-triphenyltetrazolium chloride (Sigma, St. Louis, MO. U.S.A.). Infarct volumes were quantified with a standard computer-assisted image analysis technique. To exclude pos sible confounding effects of brain swelling, an indirect method was used to calculate the lesion volumes (Lin et aI., 1993) .
Preparation of tissue extracts
At 1, 3, 6, 12, and 24 hours after the onset of ischemic insult, mice (n = 3 per time point) were deeply anesthetized with halothane and then transcardially perfused with ice-cold PBS (pH 7.4). Sham-operated control mice were similarly perfused at 24 hours. Brains were removed quickly and divided into ipsilateral ischemic hemispheres and contralateral non ischemic hemispheres.
Hemispheric tissue was frozen immediately in liquid nitro gen and stored at -80°C. Brain samples were homogenized in lOx volume lysis buffer (50 mmollL Tris-HCI, pH 7.4, ISO mmol/L NaCl, 1 % Nonidet P-40, 0.1 % SDS, 0.1 % deoxycholic acid), including protease inhibitors (2 j.1g/mL leupeptin, 2 J.Lg/mL aprotinin, I mmollL PMSF) on ice using a Teflon glass homogenizer. After centrifugation (10,000 g) for 5 min utes at 4°C, the supernatant fluid was collected. Total protein concentration of each sample was determined using the Brad ford assay (Bio-Rad Laboratories, Hercules, CA, U.S.A.).
Western blot analysis
To investigate the protein expression patterns in control and ischemic brains, equal volumes (10 J.LL) of total protein extracts were prepared and normalized for protein concentration (3 J.Lgl J.LL). Ten microliters of 2x sample buffer (126 mollL Tris-HCI, 20% glycerol, 2% SDS, 0.005% bromophenol blue) was added to each protein extract. Each sample (30 J.Lg/20 J.LL) was sepa rated by 4% to 20% gradient Tris-Glycine SDS-PAGE and transferred to polyvinylidene difluoride membrane. The mem brane was blocked with 10% nonfat dry milk in PBS containing 0.1 % Tween-20 (PBS-T). MMP-9 was detected with rabbit polyclonal antibody (kind gift from Robert Senior) at a dilution rate of I :4000. This antibody is able to recognize both latent and activated form of MMP-9 protein because it was raised against catalytic domain of mouse MMP-9 protein (Betsuyaku et aI., 2000) . After washing with PBS-T, the membrane was incubated with peroxidase-conjugated secondary antibody at room temperature for I hour. Finally, MMP-9 protein was de tected by using chemical luminescence (ECL; Amersham Phar macia Biotech, Piscataway, NJ, U.S.A.). analysis for MMP-9 mRNA. Reactions were performed using a kit from TaKaRa, Kyoto, Japan. The following conditions were adopted for the RT reaction using oligo-dT primers: 55°C for 20 minutes, 99°C for 5 minutes, 5°C for 5 minutes. The fol lowing conditions were adopted for the PCR amplification us ing specific primers: cDNA products of the RT reaction were denatured for 2 minutes at 94°C before 30 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 90 seconds.
SDS-PAGE zymogram
Primers for MMP-9 specific amplification were as follows: (5') primer 5'-GGACAGCGAGACACTAAAGGA-3' and (3') primer 5 '-AAACCCCACTTCTIGTCAGC-3 , (Peri des et aI., 1999). Control mouse f3-actin cDNA was amplified using: (5 ') primer 5'TGGAATCCTGTGGCATCCATGAAAC-3' and (3') primer 5 '-TAAAACGCAGCTCAGTAACAGTCCG-3 , (Ya mamoto and Loskutoff, 1996) . The RT-PCR products were separated on 1.8% agarose gel and visualized with ethidium bromide.
Statistical analysis
Quantitative data were expressed as mean ± SD. Ischemic lesion volumes in various groups were compared using analysis of variance followed by Tukey-Kramer tests. For comparing neurologic deficits between groups, the non parametric Kruskal-Wallis tests were used followed by Mann-Whitney tests. Differences with P < 0.05 were considered statistically significant.
RESULTS
MMP-9 protein expression is up-regulated after permanent focal cerebral ischemia
In Western blot analysis, MMP-9 protein expression was detected as early as 3 hours after the start of the focal ischemic insult, and expression continuously increased up to 24 hours (Fig. 1) (Fig. 1) . No MMP-9 expression was seen in sham-operated brains or normal contralateral brain (Fig. 1) .
Zymograms of MMP-9 activity was performed using gelatin as substrate. Increased MMP-9 levels were de tected beginning as early as 1 hour postischemia, and continuing for up to 24 hours (Fig. 2) . Similar to the Western blot findings, MMP-9 was predominantly ex pressed as the higher molecular weight latent form (105 kDa). However, at 12 to 24 hours, faint bands of activity were also observed at 97 kDa, suggesting that small amounts of activated MMP-9 were present. Incubation of ischemic brain extracts with the chemical MMP activator APMA appeared to convert all the 105 kDa protein into a band at 97 kDa, corresponding with the expected size of activated MMP-9 protein (Fig. 2) . MMP-9 was not detected in sham-operated brains or contralateral non ischemic brain (Fig. 2) .
In ischemic brain samples after 12 and 24 hours, faint bands of gelatinolytic activity were detected at approxi mately the same level as the human MMP-2 standard. These may represent low level induction of MMP-2 after cerebral ischemia in this model; however, these levels were much lower compared with MMP-9.
Transcriptional expression of MMP-9 is increased after permanent focal cerebral ischemia To determine whether the ischemic up-regulation of MMP-9 protein expression is caused by increased tran scriptional activity, RT-PCR was used to analyze levels of MMP-9 mRNA. Low levels of MMP-9 mRNA ap peared to be present in sham-operated brains (Fig. 3,  top) . At 12 and 24 hours after permanent focal cere bral ischemia, MMP-9 mRNA levels were increased (Fig. 3, top) . No bands were detected in a negative con trol reaction without the presence of reverse transcriptase (Fig. 3, top) , indicating that detection of the MMP-9 ban d s was derived from mRNA not genomic DNA. A control experiment using the same RT-PCR condition in samples from 24-hour ischemic brain showed that the amount of final RT-PCR products was proportionally related to the amount of input RNA sample within the range of 0.03 to 1 fLg after 30 cycles of amplification (Fig. 3, middle) . Intensities of the B-actin band for each time point were equal, demonstrating that comparable amounts of RNA were used for the RT-PCR analysis (Fig. 3, bottom) .
Ischemic lesion volumes are reduced in MMP-9 deficient knockout mice
There were no differences in physiologic parameters between MMP-9 knockout mice and wild type litter mates (Table I) . Furthermore, there appeared to be no differences in the gross vascular anatomy of the Circle of Willis and major cerebral arteries. Zymograms demonstrate the up-regulation of MMP-9 after focal cerebral ischemia. Once again, generally the 105 kDa zymogen was detected, although these zymograms also showed some gelatinolytic activity at 97 kDa, corresponding with the cleaved/activated enzyme. MMP-9 was detected as early as 1 hour and continued to increase until 24 hours. Sham-operated brain (S) did not show MMP-9 up-regulation. (24h APMA) Represents samples from ischemic brain activated by the MMP activator p-aminophenylmercuric acetate, thus converting the 105 kDa zymogen into the 97 kDa enzyme. (24h contra and 24h KO) Represent samples from contralateral brain and ischemic brain, respectively, from MMP-9 knockout mice at 24 hours. Subtle gelatinolytic activity was also present close to the molecular weight for MMP-2. Note that under the nonreducing conditions used in the authors' preparations, it is well known that the 72 kDa MMP-2 appears at a lower level (approximately 65 kDa). Murine MMP-9 and human MMP-2 were used as standards. n = 3 brains per lane. Laser-Doppler f10wmetry demonstrated that consis tent levels of ischemia were achieved in all animals. There were no differences between MMP-9 knockout mice and wild type littermates in terms of reduction of regional cerebral blood flow (Table 2) . 11.7 ± 4.7 12.8 ± 6.6
11.0 ± 6.8 10.0 ± 3.S 10.3 ± 6.3
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13.5 ± 5.3
Values are given as mean ± SD. Regional cerebral blood flow is expressed as a percentage of preischemic baselines. MMP-9 KO, me talloproteinase-9 knockout mice.
MMP-9 knockout mice were more resistant to focal cerebral ischemia compared with wild type littermates. To eliminate potential confounds of sex differences, data were analyzed separately in male and female mice. In both sexes, MMP-9 deficiency resulted in significantly smaller ischemic lesion volumes after 24 hours of per manent focal cerebral ischemia (Fig. 4A to 4D ). Overall, there appeared to be no differences between males and females. At 24 hours, neurologic deficits were slightly less severe in MMP-9 knockout mice compared with wild types, but the difference did not reach statistical significance (Table 3) .
To confirm that MMP-9 was indeed absent in the knockout mice, Western blot and zymographic analysis were performed on brain extracts derived from MMP-9 knockout mice at 24 hours after focal cerebral ischemia. As expected, no expression of MMP-9 protein was de tected (Figs. I and 2) . Interestingly, however, a faint band of gelatinolytic activity was observed at approxi mately 72 kDa, corresponding with a potential up regulation of MMP-2 in the ischemic MMP-9 knockout mice (Fig. 2) .
BB-94 reduces ischemic lesion volumes in wild type mice
Intraperitoneal administration of the broad spectrum MMP inhibitor BB-94 (50 mg/kg) at 30 minutes before and 3 hours after focal ischemia significantly reduced ischemic lesion volumes at 24 hours (Fig. SA to 5B) . Concomitantly, neurologic deficits were significantly Values are given as mean ± SD. RT, rectal temperature; MABP, mean arterial blood pressure; MMP-9 KO. metalJoproteinase-9 knockout mice.
M. ASAH1 ET AL. Table 3) . Systemic physiologic param eters including mean arterial blood pressure, rectal core temperature, and arterial blood pH, and gases were not significantly altered by BB-94 (Table 1) . There were no differences in regional cerebral blood flow between con trols and treated animals ( Table 2) .
BB-94 does not reduce ischemic lesion volumes in MMP-9 deficient knockout mice MMP-9 deficient knockout mice were subjected to permanent focal cerebral ischemia, and BB-94 treated animals were compared with controls given vehicle alone. Once again, two doses of BB-94 were adminis tered 30 minutes before and 3 hours after ischemic onset (50 mg/kg per dose). BB-94 did not alter physiologic parameters in the MMP-9 knockout mice ( Table I) . After induction of focal ischemia, there were no differences in regional cerebral blood flow between controls and BB-94-treated mice (Table 2) . At 24 hours, there were no significant differences in ischemic lesion sizes between treated and control MMP-9 knockout mice (Fig. 6A to  6B ). Correspondingly, there were also no differences in neurologic outcomes (Table 3) .
DISCUSSION
Recently, there have been several studies documenting the up-regUlation of MMPs after cerebral ischemia (Gasche et ai., 1999; Heo et ai., 1999; Romanic et ai., 1998; Rosenberg et ai., 1996 Rosenberg et ai., , 1998 ). In the current re port, we demonstrate that MMP-9 may play a deleterious role in ischemic pathophysiology. Protein and mRNA levels of MMP-9 were up-regulated in mouse brain after focal cerebral ischemia. MMP-9-deficient knockout mice had significantly smaller ischemic lesions com pared with their wild type littermates. The broad spec trum MMP inhibitor BB-94 reduced ischemic brain dam age in wild type mice, but not in MMP-9 knockout mice.
Precise pathways involved in regulating MMP expres sion after ischemia remain unclear. Because the gene (Fini et a!., ] 998; Nagase and Woessner, 1999) . It is known that cjos and c-jun are rapidly up-regulated after cerebral ischemia . Another up stream regulating pathway may involve mitogen activated protein kinase (MAPK) signal transduction (Fini et a!., 1998; Nagase and Woessner, 1999) . Various MAPKs have been shown to be up-regulated after isch emia-reperfusion (Abe et a!., 2000) , and inhibition of MAPK pathways have been shown to decrease ischemic brain damage (Alessandrini et a!., 1999) . In addition, a related mechanism may involve reactive oxygen species. Oxidative stress mediates a large part of the pathophysi ology of cerebral ischemia (Chan, 1996) . Recently, it has been shown that after brain trauma, MMP expression is reduced in mutant mice overexpressing superoxide dis mutase (Morita-Fujimura et a!., 1999). Interactions be tween oxidative stress and the proteolytic cascade sub served by MMPs may ultimately mediate the progression and maturation of the ischemic lesion.
As expected, no significant MMP-9 was detectable in normal brain, which is consistent with the understanding that MMP-9 is not constitutively expressed in mamma lian brain (Gasche et aI., 1999; Heo et a!., 1999; Rosen berg et aI., 1996) . However, after ischemic brain injury, MMP-9 protein levels increased as early as 3 hours after injury and lasting until at least 24 hours, at which time ischemic lesions were assessed in the current study. In creased MMP-9 protein appeared to be mediated by up regulated transcription, as shown by elevated mRNA lev els. Nevertheless, it will be important to carefully docu ment the temporal profile of MMP-9 levels over longer periods of time in future studies to fully understand its contribution to long-term outcomes. Long-term reorga nization of brain after stroke may also involve additional MMP activity. It is possible that a balance may exist between acute deleterious effects of MMPs versus po tentially beneficial effects of MMPs that subserve re modeling in the chronic phase of stroke recovery. In the current study, genetic and pharmacologic ap proaches were used to make a mechanistic connection between increased levels of MMP-9 protein and brain tissue damage. However, we did not directly measure proteolytic activity and cannot unequivocally exclude the effects of some undefined activity of MMP-9. In addi tion, the MMP-9 protein detected was primarily the 105 kDa proenzyme zymogen. Very little of the truncated form of the enzyme associated with proteolytic activity in vitro was detectable. This in vivo finding is often reported (Fini et a!., 1996; Matsubara et a!., 1991; Mohan et a!., 2000) and is not inconsistent with functionality of MMP-9 as a protease in vivo. A number of studies sug gest that enzymatic activation of MMP-9 proenzyme oc curs by binding at the cell surface, and activated enzyme is then rapidly degraded to prevent excess 120 -('t') 100 E 580
actIvIty (Yu and Stamenkovic, 1999) . Therefore, only very low levels of active MMP-9 may be present in tissue at any given time.
The current zymographic data show that after isch emic brain injury, the primary gelatinase elevated was MMP-9. Only faint zones of activity were observed at the corresponding band for MMP-2. It is possible that low but important levels of MMP-2 were not detected in the current study because the authors did not use purifi cation schemes that have been used by others to amplify the measurements of endogenous brain MMPs (Gasche et aI., 1999; Morita-Fujimura et a!., 1999) . In a study of cerebral ischemia in the nonhuman primate baboon brain, elevations in MMP-2 activity were observed (Heo et aI., 1999) .
Although the current data demonstrate that MMP-9 may contribute to brain damage after ischemia, the pre cise mechanisms that underlie its deleterious effects re main to be defined. In previous studies, an emphasis has been placed on the fact that MMP-9 can digest several matrix proteins present in the vascular basal lamina in cluding collagen, fibronectin, and laminin. Damage to vascular integrity would then lead to disrupted blood brain barrier function and increased vasogenic edema (Gasche et aI., 1999; Heo et aI., 1999; Rosenberg et aI., 1996) . However, matrix proteins such as laminin may also be found in brain parenchyma (for example, hippo campus and cerebellum), and loss of parenchymal lam inin may affect cell-matrix interactions and cell survival (Chen and Strickland, 1997) . Therefore, it remains con ceivable that MMP-mediated matrix protein degradation may disrupt cell-matrix interactions beyond the vascular compartment as well, and further contribute to neuronal cell damage (Heo et aI., 1999) . A pathophysiologic role for MMPs may extend to other forms of acute brain injury. We recently have shown that MMPs are up regulated after traumatic brain injury, and MMP-9 knockout mice are similarly protected in terms of both morphologic damage and functional motor recovery (Wang et aI., 2000) .
There are a few caveats associated with the current study. First, we only measured ischemic lesion volumes at an early time (24 hours). We cannot exclude the pos sibility that long-term effects may occur that overwhelm the acute protective effects of MMP-9 gene knockout. Second, we do not have data on the cell types that serve as sources for MMP-9. It is well known that macro phages and neutrophils can be an important source for MMPs and other deleterious proteases (Pagenstecher et aI., 1998) , and inflammatory macrophage and neutrophil infiltration is clearly an important event after cerebral ischemia. However, it has been shown that resident brain cells (neurons, astrocytes, oligodendrocytes) (Gottschall and Deb, 1996; Gottschall and Yu, 1995; Oh et aI., 1999; Zuo et aI., 1998) 1986) can also produce MMPs. It will be important to carefully define the cellular sources of deleterious MMP activity after ischemic brain injury. Finally, the MMP family comprises many other members besides MMP-9. MMPs (along with tissue inhibitors of MMP and plas minogen activators) form a complex protease cascade that may bear some similarity to the caspase cascade in terms of amplifying cell death (Cuzner and Opdenakker, 1999) . Much like the case with caspases, where caspase-3 may be a possible final executioner, it has also been proposed that MMP-9 may be a terminal member of the MMP cascade (Cuzner and Opdenakker, 1999) . Nev ertheless, it will be critical to assess the roles for more upstream signaling pathways using other specific anti bodies, inhibitors, and knockout mouse models.
In conclusion, the current study documented the role for MMP-9 in a mouse model of focal cerebral ischemia. Genetic and pharmacologic inhibition of MMP-9 signifi cantly reduced ischemic brain damage. Importantly, the broad spectrum MMP inhibitor BB-94 did not protect ischemic brain in MMP-9 knockout mice, suggesting that MMP-9 plays a critical and deleterious role in the patho physiology of ischemic brain injury. Further studies are warranted to assess the interactions between MMP-9 and other proteolytic enzymes in cerebral ischemia.
